To update and integrate the recommendations for ankylosing spondylitis and the
recommendations for the use of tumour necrosis factor inhibitors (TNFi) in axial …

Crohn disease is a chronic idiopathic inflammatory bowel disease condition characterized
by skip lesions and transmural inflammation that can affect the entire gastrointestinal tract …

This paper is the second in a series of two publications relating to the European Crohn's and
Colitis Organisation [ECCO] evidence-based consensus on the diagnosis and management …

Background The interleukin-23 pathway is implicated genetically and biologically in the
pathogenesis of Crohn's disease. We aimed to assess the efficacy and safety of …

Objectives A systematic review was conducted to explore the immunogenicity of biologic
agents across inflammatory diseases and its potential impact on efficacy/safety. Methods …

Objective Tofacitinib is an oral, small-molecule Janus kinase inhibitor that is being
investigated for IBD. We evaluated the efficacy and safety of tofacitinib for induction and …

Perianal fistulizing Crohn's disease has a major negative effect on patient quality of life and
is a predictor of poor long-term outcomes. Factors involved in the pathogenesis of perianal …

Background & Aims MEDI2070 is a human monoclonal antibody that selectively inhibits
interleukin 23 (IL23), a cytokine implicated in the pathogenesis of Crohn's disease (CD). We …

Background & Aims Ustekinumab, an inhibitor of the p40 subunit of interleukins 12 and 23,
is an effective treatment for patients with Crohn's disease (CD). Trough concentrations of …

Background Women with chronic inflammatory diseases face uncertainty regarding the
safety of biologics during breast feeding. CRADLE was the first industry-sponsored study to …